-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Vapendavir diphosphate
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1198151-75-5.gif)
| Category | Enterovirus (EV) |
| CAS | 1198151-75-5 |
| Description | Vapendavir diphosphate, an effective enterovirus capsid binder (CB), has strong antiviral activity against the replication of enterovirus 71 (EV71) with EC50s of 0.5-1.4 μM in different EV71 strains. |
Product Information
| Synonyms | BTA798 diphosphate; 1,2-Benzisoxazole, 3-ethoxy-6-(2-(1-(6-methyl-3-pyridazinyl)-4-piperidinyl)ethoxy)-, phosphate (1:2); 3-Ethoxy-6-(2-(1-(6-methylpyridazin-3-yl)piperidin-4-yl)ethoxy)benzo[d]isoxazole bis(phosphate); 3-Ethoxy-6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-1,2-benzoxazole phosphate (1:2) |
| IUPAC Name | 3-ethoxy-6-[2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy]-1,2-benzoxazole;phosphoric acid |
| Molecular Weight | 578.45 |
| Molecular Formula | C21H32N4O11P2 |
| Canonical SMILES | CCOC1=NOC2=C1C=CC(=C2)OCCC3CCN(CC3)C4=NN=C(C=C4)C.OP(=O)(O)O.OP(=O)(O)O |
| InChI | InChI=1S/C21H26N4O3.2H3O4P/c1-3-26-21-18-6-5-17(14-19(18)28-24-21)27-13-10-16-8-11-25(12-9-16)20-7-4-15(2)22-23-20;2*1-5(2,3)4/h4-7,14,16H,3,8-13H2,1-2H3;2*(H3,1,2,3,4) |
| InChIKey | MIUFDXZDQWMWRR-UHFFFAOYSA-N |
| Purity | ≥98% |
| Solubility | Soluble in DMSO |
| Appearance | Light yellow to yellow (Solid) |
| Storage | Store at 2-8°C, sealed storage, away from moisture |
| In Vitro | Vapendavir (BTA798) efficiently inhibit the in vitro replication of 21 EV71 strains/isolates that are representative of the different genogroups A, B, and C. |
| Target | EC50: 0.5-1.4 μM (EV71 strains) |
